These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 27666284)

  • 1. Influence of the watch and wait strategy on clinical outcomes of patients with follicular lymphoma in the rituximab era.
    Yuda S; Maruyama D; Maeshima AM; Makita S; Kitahara H; Miyamoto KI; Fukuhara S; Munakata W; Suzuki T; Kobayashi Y; Tajima K; Taniguchi H; Tobinai K
    Ann Hematol; 2016 Dec; 95(12):2017-2022. PubMed ID: 27666284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Watchful waiting in low-tumor burden follicular lymphoma in the rituximab era: results of an F2-study database.
    Solal-Céligny P; Bellei M; Marcheselli L; Pesce EA; Pileri S; McLaughlin P; Luminari S; Pro B; Montoto S; Ferreri AJ; Deconinck E; Milpied N; Gordon LI; Federico M
    J Clin Oncol; 2012 Nov; 30(31):3848-53. PubMed ID: 23008294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The outcome of watchful waiting in patients with previously treated follicular lymphoma.
    Fujino T; Maruyama D; Maeshima AM; Saito Y; Ida H; Hosoba R; Yuda S; Makita S; Fukuhara S; Munakata W; Suzuki T; Kuroda J; Izutsu K
    Cancer Med; 2022 May; 11(10):2106-2116. PubMed ID: 35129305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of "watch and wait" in intestinal follicular lymphoma in rituximab era.
    Tari A; Asaoku H; Takata K; Fujimori S; Tanaka S; Fujihara M; Koga T; Yoshino T
    Scand J Gastroenterol; 2016 Mar; 51(3):321-8. PubMed ID: 26382560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era.
    Belotti A; Doni E; Bolis S; Rossini F; Casaroli I; Pezzatti S; Pogliani EM; Pioltelli PE
    Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):208-13. PubMed ID: 25468321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frontline rituximab monotherapy induction versus a watch and wait approach for asymptomatic advanced-stage follicular lymphoma: A cost-effectiveness analysis.
    Prica A; Chan K; Cheung M
    Cancer; 2015 Aug; 121(15):2637-45. PubMed ID: 25877511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes of Treatment in Slovene Follicular Lymphoma Patients.
    Južnič Šetina T; Borštnar S; Jezeršek Novaković B
    Clin Lymphoma Myeloma Leuk; 2015 Oct; 15(10):586-91. PubMed ID: 26423702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The incidence of biopsy-proven transformation in follicular lymphoma in the rituximab era. A retrospective analysis from the Czech Lymphoma Study Group (CLSG) database.
    Janikova A; Bortlicek Z; Campr V; Kopalova N; Benesova K; Hamouzova M; Belada D; Prochazka V; Pytlik R; Vokurka S; Pirnos J; Duras J; Mocikova H; Mayer J; Trneny M
    Ann Hematol; 2018 Apr; 97(4):669-678. PubMed ID: 29318369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of the introduction of rituximab in first-line follicular lymphoma: a retrospective study of 247 unselected patients referred to a single institution with a long-term follow-up.
    Nicolas-Virelizier E; Ségura-Ferlay C; Ghesquières H; Chassagne-Clément C; Gargi T; Biron P; Belhabri A; Rey P; Faurie P; Chabaud S; Sebban C
    Hematol Oncol; 2015 Mar; 33(1):1-8. PubMed ID: 24496668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Follicular lymphoma: first-line treatment without chemotherapy for follicular lymphoma.
    Reagan PM; Friedberg JW
    Curr Treat Options Oncol; 2015 Jul; 16(7):32. PubMed ID: 26031546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiotherapy Compared to Other Strategies in the Treatment of Stage I/II Follicular Lymphoma: A Study of 404 Patients with a Median Follow-Up of 15 Years.
    Barzenje DA; Cvancarova Småstuen M; Liestøl K; Fosså A; Delabie J; Kolstad A; Holte H
    PLoS One; 2015; 10(7):e0131158. PubMed ID: 26147646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Addition of Rituximab to Involved-Field Radiation Therapy Prolongs Progression-free Survival in Stage I-II Follicular Lymphoma: Results of a Multicenter Study.
    Ruella M; Filippi AR; Bruna R; Di Russo A; Magni M; Caracciolo D; Passera R; Matteucci P; Di Nicola M; Corradini P; Parvis G; Gini G; Olivieri A; Ladetto M; Ricardi U; Tarella C; Devizzi L
    Int J Radiat Oncol Biol Phys; 2016 Mar; 94(4):783-91. PubMed ID: 26972651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group.
    Alonso-Álvarez S; Magnano L; Alcoceba M; Andrade-Campos M; Espinosa-Lara N; Rodríguez G; Mercadal S; Carro I; Sancho JM; Moreno M; Salar A; García-Pallarols F; Arranz R; Cannata J; Terol MJ; Teruel AI; Rodríguez A; Jiménez-Ubieto A; González de Villambrosia S; Bello JL; López L; Monsalvo S; Novelli S; de Cabo E; Infante MS; Pardal E; García-Álvarez M; Delgado J; González M; Martín A; López-Guillermo A; Caballero MD
    Br J Haematol; 2017 Sep; 178(5):699-708. PubMed ID: 28782811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Children and adolescents with follicular lymphoma have an excellent prognosis with either limited chemotherapy or with a "Watch and wait" strategy after complete resection.
    Attarbaschi A; Beishuizen A; Mann G; Rosolen A; Mori T; Uyttebroeck A; Niggli F; Csoka M; Krenova Z; Mellgren K; Kabickova E; Chiang AK; Reiter A; Williams D; Burkhardt B;
    Ann Hematol; 2013 Nov; 92(11):1537-41. PubMed ID: 23665980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Adverse Consequences of Initial Watchful Waiting for Patients With Follicular Lymphoma.
    Davies GA; Ghosh S; Oh DH; Manna M; Peters AC; Stewart CA; Stewart DA
    Clin Lymphoma Myeloma Leuk; 2018 Dec; 18(12):829-835. PubMed ID: 30243571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathological factors and tumor microenvironment markers predicting watch-and-wait discontinuation in 82 patients with follicular lymphoma.
    Yuda S; Miyagi Maeshima A; Taniguchi H; Ito Y; Hatta S; Suzuki T; Makita S; Fukuhara S; Munakata W; Suzuki T; Maruyama D; Izutsu K
    Eur J Haematol; 2021 Jul; 107(1):157-165. PubMed ID: 33905571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is there a role for "watch and wait" in follicular lymphoma in the rituximab era?
    Kahl B
    Hematology Am Soc Hematol Educ Program; 2012; 2012():433-8. PubMed ID: 23233615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A population-based study of prognosis in advanced stage follicular lymphoma managed by watch and wait.
    El-Galaly TC; Bilgrau AE; de Nully Brown P; Mylam KJ; Ahmad SA; Pedersen LM; Gang AO; Bentzen HH; Juul MB; Bergmann OJ; Pedersen RS; Nielsen BJ; Johnsen HE; Dybkaer K; Bøgsted M; Hutchings M
    Br J Haematol; 2015 May; 169(3):435-44. PubMed ID: 25709094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Has the time to come leave the "watch-and-wait" strategy in newly diagnosed asymptomatic follicular lymphoma patients?
    Rueda A; Casanova M; Redondo M; Pérez-Ruiz E; Medina-Pérez A
    BMC Cancer; 2012 May; 12():210. PubMed ID: 22650448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes following watchful waiting for stage II-IV follicular lymphoma patients in the modern era.
    Nastoupil LJ; Sinha R; Byrtek M; Ziemiecki R; Zhou X; Taylor M; Friedberg JW; Link BK; Cerhan JR; Dawson K; Flowers CR
    Br J Haematol; 2016 Mar; 172(5):724-34. PubMed ID: 26729445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.